NOTE: The following includes references to in the online news media. If you are interested in seeing the full article you will need to contact archives department of the source publication. We do not have copies of any articles described on this site.

Abgenix (ABGX)

Abgenix

ImmunoGen, Inc. Announces that Centocor Has Licensed Certain ...
[excerpt] Aventis, Genentech, Biogen Idec, Boehringer Ingelheim, Centocor, Millennium Pharmaceuticals, Inc., and Abgenix have licensed the right to develop or test TAP ... [/excerpt]
On 28 Dec 2004 in Business Wire (press release)

Abgenix Announces Pricing of Private Offering of Convertible ...
[excerpt] FREMONT, Calif.--(BUSINESS WIRE)--Dec. 15, 2004--Abgenix, Inc. (Nasdaq:ABGX) today announced it has priced its previously announced ... [/excerpt]
On Dec 15, 2004 in Business Wire (press release)

Abgenix Announces Proposed Private Offering of Convertible Senior ...
[excerpt] Abgenix, Inc. (Nasdaq:ABGX) today announced that it intends, subject to market and other conditions, to sell approximately $150 ... [/excerpt]
On Dec 15, 2004 in New Ratings

Abgenix Announces Pricing of Private Offering of Convertible ...
[excerpt] Abgenix, Inc. (Nasdaq:ABGX) today announced it has priced its previously announced private placement under Rule 144A in an aggregate ... [/excerpt]
On Dec 15, 2004 in New Ratings

XOMA Appoints Robert S. Tenerowicz, Vice President, Project and ...
[excerpt] Genesys, Inc. and then at its subsidiary, Abgenix, Inc., for three years before joining GenVec. While at Abgenix, Mr. Tenerowicz ... [/excerpt]
On Dec 20, 2004 in Business Wire (press release)

Sequenom soars; biotech, pharma benchmarks trade mixed
[excerpt] Another decliner was antibody developer Abgenix (ABGX), which said it plans to sell $150 million worth of convertible senior notes due in 2011. ... [/excerpt]
On Dec 15, 2004 in Investor's Business Daily (subscription)

Morphotek Issued US Patent 6,825,038 for Generating Genetically ...
[excerpt] Morphotek has formed successful collaborations that implement its proprietary technology for discovery and product development with Abgenix, Centocor, The ... [/excerpt]
On Dec 13, 2004 in PR Newswire (press release)

ImClone Outlook Hurt By Genentech's Avastin Data
[excerpt] ...this data," and also cited potential competition for the colorectal cancer market in 2006 from Amgen (nasdaq: AMGN - news - people ) and Abgenix (nasdaq: ABGX ... [/excerpt]
On Nov 29, 2004 in Forbes

Cell Genesys Reports Encouraging Follow Up Clinical Data From ...
[excerpt] ...disorders. Cell Genesys also continues to hold an equity interest in its former subsidiary, Abgenix, Inc., an antibody products company. ... [/excerpt]
On Dec 7, 2004 in mysan.de

CuraGen Receives Fast Track Designation for CG53135
[excerpt] CuraGen has established broad development alliances with Abgenix, TopoTarget, and Bayer, and its experienced teams are advancing the Company's pipeline of ... [/excerpt]
On Dec 2, 2004 in mysan.de

Single Dose Phase I Data on CG53135 for the Prevention of Oral ...
[excerpt] CuraGen has established broad development alliances with Abgenix, TopoTarget, and Bayer, and its experienced preclinical and clinical teams are advancing the ... [/excerpt]
On Dec 4, 2004 in Yahoo News (press release)

Pfizer Sees Strong Prospects from the Industryā€™s Premier R&D ...
[excerpt] ...treatment,ā€? he said. CP-675,206 is a potential cancer medicine developed in collaboration with Abgenix. Unlike traditional chemotherapy ... [/excerpt]
On Dec 1, 2004 in PharmaLive.com (press release)

Dendreon's APC8024 Immunotherapy Shows Promise in Advanced Breast ...
[excerpt] ...product candidates. Dendreon has research and development alliances with Genentech, Inc., Abgenix, Inc. and Dyax Corp. For more ... [/excerpt]
On Dec 11, 2004 in Yahoo News (press release)

Quantitative Analysis of Global Biopharmaceutical Manufacturing
[excerpt] P: +91-22-2832-4705 Ext: 131 E: sdedhia@frost.com http://www.frost.com List of industry participants: Abbott, Abbott Bioresearch Center, Abgenix, Wyeth, Amgen ... [/excerpt]
On Nov 30, 2004 in PR Newswire (press release)